None listed
Conditions
Brief summary
This will be an audit to provide preliminary data to address whether the use of Plasma-Lyte148 'Registered Trademark' as default intravenous fluid results in better clinical outcomes compared to current standard practice. The audit will be conducted with two 12 week periods. During the control period patients admitted to Wellington Regional Hospital from ED would have received intravenous fluid at the discretion of the treating doctors, in which 0.9% saline would have been the preferred intravenous fluid. This will be compared a 12 weeks where the preferred fluid will be Plasma-Lyte148 'Registered Trademark'. The outcomes that will be recorded will be kidney function, hospital length of stay, intensive care admission and mortality.
Interventions
Single centre, open label, before and after audit.
One month prior to the intervention period there will be Emergency Department (ED) staff education and logistic arrangements for changing to Plasma-Lyte 148 'Registered Trademark' as the default IV fluid. During the 12 week intervention period Plasma-Lyte 148 'Registered Trademark' will be used as the default primary crystalloid fluid. The dosing regimen is at the discretion of the treating clinician.
A random sample of 100 patients that rece
Single centre, open label, before and after audit. One month prior to the intervention period there will be Emergency Department (ED) staff education and logistic arrangements for changing to Plasma-Lyte 148 'Registered Trademark' as the default IV fluid. During the 12 week intervention period Plasma-Lyte 148 'Registered Trademark' will be used as the default primary crystalloid fluid. The dosing regimen is at the discretion of the treating clinician. A random sample of 100 patients that received fluid in emeregency department will be assessed to see extact type and amount of given.
Sponsors
Medical Research Institute of New Zealand
Study design
Allocation
Non-randomised trial
Intervention model
Other
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients >18 year presenting to ED and subsequently admitted to hospital who have a serum creatinine measured in the ED
Exclusion criteria
Patients on renal replacement therapy for end stage renal failure.
Outcome results
None listed